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Background:Dual antiplatelet treatment (DAPLT) for at least 12 months is recommended after drug eluting stent
(DES) implantation, but concerns regarding the extended use of this treatment persist due to increased risk of
bleeding. In this study are assessed the incidence, correlates, and clinical signiﬁcance of bleeding complications
in diabetic patients after long-term DAPLT post DES implantation.
Methods:We studied 610 consecutive diabetic patients after DES implantation. The primary end point was the
occurrence of any bleeding according to the BARC and TIMI deﬁnitions.
Results: The incidence of overall bleeding was higher in patients on DAPLT (21.1% vs. 4.4%, p b 0.001); minor/
minimal according to the TIMI deﬁnition, and type 1 or 2 according to the BARC deﬁnition, weremore frequently
observed in patients on DAPLT (20.3% vs. 3.0%, p b 0.001, 15.6% vs. 2.0%, p b 0.001 and 4.4% vs. 0.5%, p = 0.034,
respectively), whereas therewas no effect on type 3 (3.5% vs. 2.0%, p=ns). DAPLTwas an independent predictor
for overall (HR 5.35, 95% CI: 2.69–10.67, p b 0.001), minor (HR 7.45, 95% CI: 3.25–17.12, p b 0.001, for TIMI
classiﬁcation) and type 1 or 2 bleeding (HR 8.17, 95% CI 3.29–20.25, p b 0.001); furthermore smoking was also
predictor for overall bleeding (HR 1.65, 95% CI: 1.05–2.61, p = 0.030). Cardiovascular adverse events were not
more frequent in patients with bleeding as compared with those without bleeding.
Conclusions: Long-termDAPLT in diabetic patients after DES implantation is associatedwith higher risk of overall
and minor but not major bleeding; smoking may have a signiﬁcant role in the occurrence of bleeding
complications.
©2014 TheAuthors. Published by Elsevier Ireland Ltd. This is an open access article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Antiplatelet agents are used for the treatment and prevention of
ischemic events in patients with established atherothrombosis or with
risk factors for vascular diseases. Although the early and late beneﬁts
of dual antiplatelet treatment (DAPLT) have been demonstrated in
multiple studies, concerns regarding the extended use of DAPLT persist.
The guidelines recommend continuing DAPLT for over 12 months after
implantation of a drug-eluting stent (DES) in patients at low risk of
bleeding [1]. Although effective, DAPLT increase the risk of bleeding
and bleeding events are associated with worse short- and long-term
outcomes [2].
Diabetesmellitus is considered as amajor risk factor for cardiovascu-
lar events, and coronary thrombosis is more often observed in suchssis Cardiac Surgery Center, 356
3356; fax: +30 2109493373.
eliability and freedom from bias
land Ltd. This is an open access articpatients, as this condition is characterized by elevated concentrations
of procoagulant factors which are up-regulated, contributing to a
prothrombotic status [3]. Diabetic patients (DP) have an increased risk
for restenosis and their clinical follow-up (FU) is often characterized
by a higher incidence of death, myocardial infarction (MI) and revascu-
larization [4,5]. For these reasons, it is not surprising that DAPLT in DP
is often maintained for more than 12 months, exposing them to a
potential increased risk of bleeding complications.
Analyses of bleeding risk among high-risk vascular patients taking
antiplatelet therapy for up to 1 year have been reported, and risk factors
have been identiﬁed [6]. In this study, we assessed the frequency,
correlates, and clinical signiﬁcance of bleeding complications, as well
as the outcome regarding major adverse cardiovascular events (MACE),
in DP treated with long-term DAPLT after DES implantation.
2. Patients and methods
In this single center prospective registry, 610 consecutive DP
(male 80%, mean age 65 ± 9 years) underwent PCI from September
1st, 2003 to June 30, 2006 with 1st generation DES implantation [80%le under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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eluting (TAXUS, Boston Scientiﬁc Co), and 10% combined] in their native
coronary arteries or aorto-coronary bypass grafts. Eligible patients had a
history of stable or unstable coronary artery disease, including acuteMI,
and a manifest diabetes mellitus treated with oral antidiabetic agent,
insulin or both; PCIwas performed to treat de novo or restenotic lesions.
Major exclusion criteria were hemorrhagic diathesis, known use of
warfarin, contraindications to the use of aspirin and thienopyridines,
and coexisting conditions that limited life expectancy to less than
12 months.
All patients were treated with oral aspirin (at least 100 mg daily)
and clopidogrel (a loading dose of 600mgwas given as soon as possible
during the procedure for those without pretreatment, followed by
75 mg daily). Patients were advised to maintain DAPLT for at least
12 months; the use of DAPLT for a longer period was encouraged and
left to the physician's discretion.3. Follow-up, endpoints and deﬁnitions
Five years clinical FU was obtained in 587/610 (96%) patients.
Clinical outcomes and bleeding complications during FU were obtained
by clinical visits in the hospital or serial direct telephone contact (every
12 months) by research fellows of our Cardiology Department and
entered into a dedicated database; in case of hospitalization full data
from hospital records were received. During the FU period, 89% of pa-
tients received DAPLT for 12 months, 68% for 2 years, 64% for 3 years,
59% for 4 years and 56% for 5 years; furthermore 376 (64%) patients
remained continuously on DAPLT, whereas 211 discontinued one of
the two antiplatelet regiments. There were no differences in demo-
graphics, clinical and procedural characteristics in patients on DAPLT
vs. single antiplatelet treatment (SAPLT) (Table 1).
The primary study end point was the occurrence of any bleeding
according to TIMI [7] or Bleeding Academic Research Consortium [8]
(BARC) deﬁnitions at clinical FU. We also assessed the MACE, deﬁned
as the combination of all-cause mortality/non-fatal MI/cerebrovascular
accident (CVA) and the occurrence of deﬁnite/probable stent thrombo-
sis according to the Academic Research Consortium (ARC) classiﬁcation
[9].Table 1





N (%) N (%) HR (95% CI) p
Age (years), mean (SD) 65.1 (8.9) 64.7 (9.4) 1.01(0.99–1.02) 0.094
Age N65 years 200(53.2) 108(51.2) 1.13(0.93–1.39) 0.223
Men 307(81.6) 164(77.7) 0.91(0.70–1.18) 0.494
Hypercholesterolemia 348 (92.6) 195 (92.4) 1.01 (0.69–1.49) 0.943
Hypertension 296 (78.7) 167 (79.1) 0.99 (0.78–1.27) 0.982
Smoking 226 (60.1) 132 (62.6) 0.98 (0.80–1.21) 0.900
IDDM 81 (21.5) 41 (19.4) 1.01 (0.89–1.14) 0.924
Previous MI 146 (38.8) 98 (46.4) 0.92 (0.75–1.14) 0.460
Previous CABG 62 (16.5) 36 (17.1) 0.99 (0.75–1.30) 0.955
ACS at presentation 136 (36.2) 65 (30.8) 1.23 (0.99–1.52) 0.052
EF b40% 36 (9.6) 24 (11.4) 0.94 (0.56–1.58) 0.825
Multivessel disease 259 (68.9) 146 (69.2) 1.03 (0.83–1.29) 0.742
Multivessel stenting 71 (18.9) 33 (15.6) 1.10 (0.85–1.42) 0.462
Complete
revascularization
170 (45.2) 87 (41.2) 1.04 (0.85–1.27) 0.700
Number of stent/patient,
median (IQR)
1 (1,2) 1 (1,2) 1.03 (0.92–1.17) 0.576
Total stent length (mm),
median (IQR)
23 (18–36) 23 (18–33) 1.00 (0.99–1.01) 0.697
IDDM: insulin dependent diabetes mellitus; MI: myocardial infarction; CABG: coronary
artery bypass graft; ACS: acute coronary syndrome; EF: ejection fraction.4. Statistical analysis
Continuous variables are presented with mean and standard devia-
tion (SD) or with median and interquartile range (IQR). Quantitative
variables are presented with absolute and relative frequencies. Life
table analyses were used to calculate cumulative free bleeding rate for
speciﬁc time intervals. Event rates were calculated dividing the number
of events occurring during the study period by the number of person-
years of observation. Incidence rates were presented as the number of
events/1000 person-years. The association of each study variable with
bleeding was assessed by univariate Cox regression analysis. Variables
that showed signiﬁcant association with the outcome were included
in the multivariate Cox proportional-hazard model in a stepwise meth-
od (p for removal was set at 0.1 and p for entry was set at 0.05) in order
to determine the independent factors for bleeding. Hypothesized inter-
actions of variables in the models were not signiﬁcant. The assumption
of proportional hazards was evaluated by testing for the interaction
with a continuous time variable. Hazard ratios (HR) with their 95%
Conﬁdence Interval (CI) were also computed to evaluate the association
of clinical FU variables (stent thrombosis, death, non-fatalMI, CVA)with
bleeding and antiplatelet treatment. Kaplan–Meier estimates for bleed-
ing events were constructed over the FU period. All p values reported
are two-tailed. Statistical signiﬁcance was set at 0.05 and analyses
were conducted using STATA statistical software (version 9.0).
5. Results
5.1. Bleeding
Two (0.3%) major periprocedural bleeding events according to TIMI
deﬁnition were observed; these events were excluded from further
analysis. Among the 587 patients with complete FU data, 90 (15.3%)
presented any bleeding event over a median of 30 months; seven out
of ninety (7.8%) were classiﬁed as having a major bleeding and 83
(92.2%) minor/minimal bleeding according to TIMI deﬁnition. Accord-
ing to BARC deﬁnition, 10.8% (n = 60) of the study patients had type
1 bleeding and 2.9% (n = 15) for each, type 2 and type 3 bleeding
(type 3a 1.6%, type 3b 1.2% and type 3c 0.2%). The most common type
of bleeding was upper gastrointestinal (32.2%), followed by bruising
(18.4%), hematuria (11.5%), nasal (6.9%), lower gastrointestinal (4.6%),
and intraocular (3.4%); intracranial bleeding occurred in 1.1% and
other types of bleeding such as gingival, menorrhagia, hemoptysis,
in 21.9%. The bleeding event rate/1000 patient-years were 34.85 (95%
CI: 28.4–42.7). Cumulative bleeding-free rate for the ﬁrst year was
97.8% [standard error (SE) 0.6%], for two years 94.5% (SE = 0.9%) and
for ﬁve years 85.9% (SE = 1.5%) (Fig. 1).
Demographics, clinical and procedural characteristics of all patients
and in association with bleeding are presented in Table 2; acute coro-
nary syndromes and smoking had a signiﬁcant role for bleeding compli-
cations (HR 1.67, 95% CI 1.10–2.53, p= 0.015 and HR 1.57, 95% CI 0.99–
2.48, p = 0.050 respectively). The results, when the association of
demographics, clinical and procedural characteristics with major or
minor/minimal bleeding according to TIMI classiﬁcation was assessed,
are shown in Table 3. There were also no differences in the baseline
characteristics between those without bleeding and those with type 1,
2 or 3 bleeding according to BARC classiﬁcation, except of acute coro-
nary syndromes and smoking which were more frequent in type 2
and type 3 bleeding respectively (Table 4). During the total FU period
any bleeding event occurred in 21.1% of patients on DAPLT and in 4.4%
of patients on SAPLT (HR 5.33, 95% CI: 2.68–10.61, p b 0.001), (Fig. 2);
all patients on SAPLT were either on aspirin (66%) or clopidogrel
(34%) treatment at the time of the event. Twenty one patients (3.6%)
had bleeding complication during the ﬁrst year of FU and all of them
were on DAPLT. Twenty of them were classiﬁed as having a minor
bleeding according to TIMI deﬁnition while 17 as having bleeding
type 1 or 2 according to the BARC deﬁnition. Excluding patients with
Fig. 1. Cumulative bleeding free rates during the follow-up period. Cumulative bleeding-free rate for theﬁrst yearwas 98.0% (SE= 0.6%), for twoyears 95.3% (SE= 0.9%) and forﬁve years
89.4% (SE = 1.3%).
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had bleeding complications vs. 4.5% of patients on SAPLT (HR 4.07, 95%
CI: 2.02–8.21, p b 0.001) during the FU period. The bleeding event rate/
1000 patient-yearswas 49.92 (95%CI: 40.4–61.6) for patients onDAPLT
and 9.3 (95% CI: 4.9–17.7) for patients on SAPLT. Cumulative bleeding-
free rate for the ﬁrst year was 96.6% (SE = 0.9%) for patients on DAPLT
and 100.0% for patients on SAPLT. Bleedingwas the cause of permanent
DAPLT discontinuation in 56% of patients with such a complication.
Major according to TIMI deﬁnition, or type 3 bleeding (Table 5),
showed no signiﬁcant different hazard between patients on DAPLT or
SAPLT; on the contrast, a signiﬁcant association of DAPLT with bleeding
types 1 and 2, such asminor/minimal bleeding complications according
to TIMI classiﬁcation was observed. When multiple Cox proportional
hazard analysis in a stepwisemethodwas conducted, DAPLT treatment,
smoking and acute coronary syndromes were predictors for overall
bleeding complications (HR 5.35, 95% CI: 2.69–10.67, p b 0.001, HR
1.65, 95% CI: 1.05–2.61, p = 0.030 and HR 1.63, 95% CI: 1.07–2.47,
p = 0.021 respectively); DAPLT treatment and acute coronary syn-
dromes were also predictors for bleeding type 1 or 2 (HR 8.17, 95% CI
3.29–20.25, p b 0.001and HR 1.58, 95% CI 1.00–2.50, p = 0.048 respec-
tively) and minor/minimal bleeding according to TIMI deﬁnition(HR
7.45, 95% CI: 3.25–17.12, p b 0.001and HR 1.61, 95% CI: 1.05–2.49,
p = 0.030 respectively).Table 2
Demographics, clinical and procedural characteristics in total and in association with bleeding.
Total (N = 587) No bleeding
N (%) N (%)
Age (years), mean (SD) 65.0 (9.1) 65.0 (9.2)
Age N65 years 308 (52.5) 262 (52.7)
Men 471 (80.2) 400 (80.5)
Hypercholesterolemia 543 (92.5) 459 (92.4)
Hypertension 463 (78.9) 393 (79.1)
Smoking 358 (61) 294 (59.2)
IDDM 122 (20.8) 107 (21.5)
Previous MI 244 (41.6) 212 (42.7)
Previous CABG 98 (16.7) 87 (17.5)
ACS at presentation 201 (34.2) 161 (32.4)
EF b40% 60 (10.2) 55 (11.1)
Multivessel disease 405 (69) 346 (69.6)
Multivessel stenting 104 (17.7) 85 (17.1)
Complete revascularization 257 (43.8) 212 (42.7)
Number of stent/patient, median (IQR) 1 (1,2) 1 (1,2)
Total stent length (mm), median (IQR) 23 (18–36) 23 (18–365.2. Clinical events
There was no difference in the incidence of all-causemortality, non-
fatal MI, and CVA in patients on DAPLT vs. SAPLT at FU (12% vs 9%, HR
1.39, 95% CI 0.83–2.32, p = 0.207 for death, 4.2% vs 3.5%, HR 1.23, 95%
CI 0.53–2.86, p = 0.617 for non-fatal MI, and 4.2% vs 3.5%, HR 1.24,
95% CI 0.54–2.88, p = 0.606 for CVA); the incidence for MACE was
18.7% and 13.7% respectively (HR 1.41, 95% CI 0.93–2.14, p = 0.10).
During the ﬁrst year of FU, 18 (3%) patients presented MACE, 15
(83.3%) of which were on DAPLT (p = 0.02); 79 patients (13.9%) pre-
sented MACE after the 1st year of FU. Patients on DAPLT after the ﬁrst
year of FU did not have signiﬁcant hazard of MACE as compared with
those on SAPLT (17% vs 15.8%, HR 1.1, 95% CI 0.64–1.87, p = 0.73).
The cumulative survival rate at 5 years was 88% in patients on DAPLT
and 91% on SAPLT. Patients with bleeding complications had no signiﬁ-
cant different hazard for stent thrombosis, death, non-fatal MI or CVA
(Table 6). The incidence of deﬁnite/probable stent thrombosis was
2.1% in patients on DAPLT and 0.8% on SAPLT (HR 1.32, 95% CI 0.27–
6.58, p = 0.73); all 4 deﬁnite and 3 probable stent thrombosis were
on DAPLTwhereas 2 probable stent thrombosis were on SAPLT. Regard-
ing the time of the events, 1 deﬁnite and 1 probable (on DAPLT)
occurred on day 7 and day 25 after PCI respectively, 2 deﬁnite occurred
during months 8 and 11 and 1 probable (on DAPLT) during month 5(Ν = 497) Bleeding (Ν = 90)
N (%) HR (95% CI) p
64.7 (8.1) 1.00 (0.98–1.02) 0.998
46 (51.1) 0.99 (0.65–1.49) 0.959
71 (78.9) 1.11 (0.67–1.84) 0.689
84 (93.3) 1.15 (0.50–2.63) 0.742
70 (77.8) 0.94 (0.57–1.55) 0.830
64 (71.1) 1.57 (0.99–2.48) 0.050
15 (16.7) 0.86 (0.65–1.14) 0.301
32 (35.6) 0.78 (0.50–1.20) 0.270
11 (12.2) 0.68 (0.36–1.28) 0.238
40 (44.4) 1.67 (1.10–2.53) 0.015
5 (5.6) 0.60 (0.24–1.48) 0.273
59 (65.6) 0.85 (0.55–1.32) 0.487
19 (21.1) 1.26 (0.76–2.10) 0.361
45 (50.0) 1.31 (0.86–1.98) 0.199
1 (1,2) 1.06 (0.83–1.36) 0.615
) 23 (18–35) 1.00 (0.99–1.02) 0.390
Table 3
Demographics, clinical and procedural characteristics in association with bleeding according to TIMI deﬁnition.
No bleeding Minor bleeding Major bleeding
N (%) N (%) N (%) HR (95% CI)a p HR (95% CI)b p
Age (years), mean 65.0 (9.2) 65 (8.1) 61 (7.3) 0.96 (0.89–1.03) 0.261 1.00 (0.98–1.03) 0.755
Age N65 years 262 (52.7) 44 (53.0) 2 (28.6) 0.39 (0.07–2.00) 0.259 1.06 (0.69–1.63) 0.787
Men 400 (80.5) 66 (79.5) 5 (71.4) 1.65 (0.32–8.54) 0.546 1.07 (0.63–1.82) 0.802
Dyslipidemia 459 (92.4) 78 (94.0) 6 (85.7) 0.50 (0.06–4.11) 0.516 1.27 (0.51–3.13) 0.605
Hypertension 393 (79.1) 66 (79.5) 4 (57.1) 0.36 (0.08–1.63) 0.187 1.03 (0.61–1.76) 0.893
Smoking 294 (59.2) 57 (68.7) 6 (85.7) 3.97 (0.47–32.98) 0.202 1.42 (0.89–2.25) 0.140
IDDM 107 (21.5) 15 (18.1) 1 (14.3) 0.18 (0.04–8.82) 0.392 0.90 (0.68–1.19) 0.475
Previous MI 212 (42.7) 29 (34.9) 3 (42.9) 1.04 (0.23–4.64) 0.959 0.76 (0.49–1.20) 0.247
Previous CABG 87 (17.5) 10 (12.0) 1 (14.3) 0.79 (0.09–6.61) 0.833 0.67 (0.35–1.30) 0.240
ACS 161 (32.4) 37 (44.6) 3 (42.9) 1.61 (0.36–7.21) 0.531 1.68 (1.09–2.60) 0.018
EF b40% 55 (11.1) 5 (6.0) 0 0.04 (0–398.2) 0.590 0.65 (0.26–1.61) 0.354
Multivessel disease 346 (69.6) 56 (67.5) 3 (42.9) 0.33 (0.07–1.50) 0.154 0.93 (0.58–1.47) 0.755
Multivessel stenting 85 (17.1) 18 (21.7) 1 (14.3) 0.81 (0.09–6.71) 0.844 1.31 (0.77–2.20) 0.314
Complete revascularization 212 (42.7) 41 (49.4) 4 (57.1) 1.77 (0.39–7.91) 0.454 1.28 (0.83–1.97) 0.261
Number of stent/patient, median (IQR) 1 (1,2) 1 (1–2) 1 (1–2) 0.80 (0.28–2.31) 0.679 1.08 (0.84–1.40) 0.534
Total stent length (mm), median (IQR) 23 (18–36) 23 (18–35) 33 (23–36) 1.00 (0.96–1.05) 0.755 1 (0.99–1.02) 0.422
a Hazard ratio (95% Conﬁdence Interval) for major bleeding.
b Hazard ratio (95% Conﬁdence Interval) for minor bleeding.
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considered as very latemonth 54 andmonths 27, 29, and 40 respective-
ly. During the FUperiod 127patients (21.6%) underwent repeat PCI pro-
cedure either for target lesion revascularization (n = 20), non-target
lesion revascularization due to disease progression (n = 89), or both
(n = 18). No signiﬁcant differences in bleeding events were observed
between this group of patients and those without repeat revasculariza-
tion (HR 1.09, 95% CI 0.68–1.74, p = 0.719).
6. Discussion
This study showed that long-termDAPLT after PCI in DP signiﬁcantly
increases the risk of overall bleeding complications, but this increase is
limited tominor bleeding, irrespective the deﬁnition is used; this excess
risk is steady for the whole period of FU. Except for the use of DAPLT,
smoking and acute coronary syndromes were also predictors for overall
bleeding, whereas bleeding did not correlate with MACE or deﬁnite/
probable stent thrombosis. Because the deﬁnition clearly plays an im-
portant role in terms of themeasured incidence of bleeding, two deﬁni-
tions were used in the current study for a better interpretation of the
results.
Unlike ischemic clinical events such as cardiac death, MI, or stent
thrombosis, there is substantial heterogeneity among the many bleedingTable 4
Demographics, clinical and procedural characteristics in association with bleeding according to
Type 1 Type 2 Type 3
N (%) N (%) N (%) HR
Age (years), mean 65 (8.5) 63 (7.2) 63 (7.0) 1.0
Age N65 years 33 (55.0) 7 (46.7) 6 (40) 1.1
Men 47 (78.3) 12 (80) 12 (80) 1.1
Dyslipidemia 55 (91.7) 14 (93.3) 14 (93.3) 0.9
Hypertension 46 (76.7) 13 (86.7) 11 (73.3) 0.8
Smoking 38 (63.3) 12 (80) 14 (93.3) 1.1
IDDM 11 (18.3) 2 (13.3) 2 (13.3) 0.9
Previous MI 22 (36.7) 5 (33.3) 5 (33.3) 0.8
Previous CABG 8 (13.3) 0 3 (20) 0.7
ACS 24 (40.0) 9 (60) 7 (46.7) 1.4
EF b40% 4 (6.7) 1 (6.7) 0 0.7
Multivessel disease 38 (63.3) 11 (73.3) 10 (66.7) 0.7
Multivessel stenting 12 (20.0) 4 (26.7) 3 (20) 1.1
Complete revascularization 31 (51.7) 7 (46.7) 7 (46.7) 1.3
Number of stent/patient, median (IQR) 1 (1–2) 1 (1–2) 1 (1–2) 1.0
Total stent length (mm), median (IQR) 23 (18–35) 23 (18–34) 26 (18–36) 1.0
a Hazard ratio (95% Conﬁdence Interval) for type 1 bleeding.
b Hazard ratio (95% Conﬁdence Interval) for type 2 bleeding.
c Hazard ratio (95% Conﬁdence Interval) for type 3 bleeding.deﬁnitions currently in use. Current bleeding deﬁnitions consist of both
laboratory parameters, such as decreases in hemoglobin and hematocrit
scores, and clinical events, including the need for transfusion or surgery,
cardiac tamponade, hematomas, and various degrees of bleeding. Each
deﬁnition incorporates a different combination of these data elements
and then rank orders these combinations into severity categories,
which vary widely between deﬁnitions. The Thrombolysis in Myocardial
Infarction (TIMI) bleeding criteria have been in use for nearly 30 years,
andhavebeen reported inmost cardiovascular trials. The need to develop
and standardize bleeding end-point deﬁnitions led the Bleeding Academ-
ic Research Consortium to propose new objective, hierarchically graded,
consensus classiﬁcation for bleeding.
In this study, regardless of the deﬁnition used, the severity of bleed-
ing was almost similar, as about 86% of patients deﬁned as having
minor/minimal bleeding according to TIMI deﬁnition presented as also
having type 1 or 2 bleeding according to BARC deﬁnition.
The prolong use of DAPLT results inmarkedly reduced risk of throm-
botic events associated with stent implantation but concerns regarding
the extended use of DAPLT persist, mainly due to the bleeding risk. The
incidence of increased bleeding with DAPLT has been well examined in
several studies. In the CURE trial, clopidogrel and aspirin therapy was
associatedwith a signiﬁcant increase inmajor andminor bleeding com-
pared with aspirin alone, but no increase in life-threatening bleedingBARC classiﬁcation.
(95% CI)a p HR (95% CI)b p HR (95% CI)c p
1 (0.98–1.04) 0.431 0.98 (0.93–1.03) 0.403 0.98 (0.93–1.03) 0.491
5 (0.69–1.92) 0.582 0.82 (0.30–2.28) 0.714 0.63 (0.22–1.79) 0.391
3 (0.61–2.10) 0.681 1.04 (0.29–3.70) 0.946 1.04 (0.29–3.68) 0.953
1 (0.36–2.27) 0.841 1.16 (0.15–8.85) 0.883 1.15 (0.15–8.77) 0.890
8 (0.48–1.59) 0.670 1.73 (0.39–7.70) 0.467 0.75 (0.24–2.35) 0.621
3 (0.67–1.91) 0.645 2.65 (0.75–9.39) 0.131 9.26 (1.21–70.42) 0.032
0 (0.65–1.25) 0.545 0.75 (0.35–1.58) 0.448 0.75 (0.36–1.58) 0.454
2 (0.48–1.39) 0.461 0.69 (0.24–2.03) 0.505 0.70 (0.24–2.03) 0.508
4 (0.35–1.56) 0.435 0.04 (0.00–12.74) 0.269 1.20 (0.34–4.25) 0.778
2 (0.85–2.38) 0.183 3.13 (1.11–8.81) 0.030 1.86 (0.67–5.15) 0.228
2 (0.26–1.99) 0.232 0.67 (0.09–5.09) 0.698 0.04 (0.0–84.85) 0.416
9 (0.46–1.33) 0.373 1.20 (0.38–3.78) 0.750 0.89 (0.30–2.61) 0.837
8 (0.62–2.22) 0.610 1.74 (0.55–5.48) 0.340 1.21 (0.34–4.28) 0.770
8 (0.83–2.29) 0.210 1.17 (0.42–3.23) 0.759 1.61 (0.42–3.20) 0.773
6 (0.78–1.43) 0.716 0.96 (0.50–1.85) 0.920 1.17 (0.66–2.07) 0.590
0 (0.99–1.02) 0.438 0.99 (0.96–1.03) 0.897 1.01 (0.98–1.04) 0.495
Fig. 2. Cumulative hazard of bleeding for patients on DAPLT vs. SAPLT treatment. Patients
on DAPLT had greater hazard for bleeding complication. DAPLT: dual antiplatelet treat-
ment, SAPLT: single antiplatelet treatment.
Table 6
Cardiovascular events in patients with and without bleeding.
Clinical follow-up No bleeding Bleeding
N (%) N (%) HR (95% CI) P
Deﬁnite/probable ST 8 (1.6) 1 (1.1) 0.69 (0.08–5.50) 0.725
Deﬁnite 3 (0.6) 1 (1.1)
Probable 5 (1.0) 0
Death 56 (11.3) 7 (7.8) 0.67 (0.30–1.48) 0.328
Non-fatal MI 19 (3.8) 4 (4.4) 1.13 (0.38–3.34) 0.815
CVA 20 (4.0) 3 (3.3) 0.80 (0.24–2.71) 0.728
All events 83 (16.7) 14 (15.6) 0.91 (0.51–1.60) 0.747
ST: stent thrombosis; MI: myocardial infarction; CVA: cerebrovascular accident.
61V. Voudris et al. / IJC Heart & Vasculature 5 (2014) 57–62events was observed [10]. Similarly, in a meta-analysis of 18 random-
ized trials, DAPLT therapy was associated with a signiﬁcantly increased
risk of major andminor bleeding events compared to single agent ther-
apy; [11] although based on small numbers, there were no signiﬁcant
differences in fatal or intracranial bleedings. In the CHARISMA trial the
rate of severe bleeding (according to GUSTO deﬁnition) was not signif-
icantly greater with DAPLT, but a signiﬁcant increase in the incidence of
moderate bleedingwas observed [12]. In the same trial, the risk ofmod-
erate or severe bleeding while on DAPLT was greater in the ﬁrst year,
but after this period the bleeding rates were similar in both groups.
Generally, in trials evaluating extended treatment with DAPLT major
bleeding rates have ranged from ~2% to ~4% [10,12,13].
Therewere 56 deaths (11.3%) in no bleeding group in this study, and
only 7 (7.8%) in bleeding group but this difference was not statistically
signiﬁcant. This is an unusual ﬁnding and someone could consider
that these patients were “prevented” from having a bleeding event by
dying. Several studies have examined the relationship between bleed-
ing, mortality and other MACE. In these studies different deﬁnitions of
bleeding were used, including not only the TIMI deﬁnitions, used in
this study, but more than a dozen others [14]. A few deﬁnitions have
been reported to be associated with mortality or other events such as
GUSTO [15] deﬁnition in the CHARISMA trial. Less severe bleeding
sometimes becomes clinically more important with long term thera-
pies, because minor bleedings may lead to discontinuation of antiplate-
let treatment by the patient. Withdrawal of DAPLT has been reported
as a cause of stent thrombosis after DES implantation; furthermore,
discontinuation of DAPLT seems to be the most potent predictor of the
late stent thrombosis, and barring a bleeding contraindication, provides
sufﬁcient reason to recommend extended DAPLT in patients treated
with DES, particularly those with acute coronary syndrome or diabetes
mellitus [16–18].
On the other hand, several trials [19,20] have shown no signiﬁcant
beneﬁt associatedwith the extended continuation of DAPLT in reducing
the incidence of cardiovascular events; in addition, a signiﬁcant increaseTable 5
Bleeding complications and antiplatelet treatment.
DAPLT N (%) SAPLT N (%) HR (95% CI) p
Overall bleeding 81 (21.1) 9 (4.4) 5.33 (2.68–10.61) b0.001
Type 3 bleeding 11 (3.5) 4 (2.0) 1.79 (0.57–5.63) 0.327
Type 2 bleeding 14 (4.4) 1 (0.5) 8.96 (1.18–68.14) 0.034
Type 1 bleeding 56 (15.6) 4 (2.0) 8.40 (3.05–23.18) b0.001
Major (TIMI) 4 (1.3) 3 (1.5) 0.87 (0.19–3.90) 0.851
Minor/minimal (TIMI) 77 (20.3) 6 (3.0) 7.58 (3.30–17.39) b0.001in the number of actionable bleeding episodes has been observed [20].
In a recent meta-analysis of randomized trials, the extension of DAPLT
duration increased the risk of TIMI major bleeding without reducing is-
chemic events [21]. In another study 6-month vs. longerDAPLT duration
was not associated with increased likelihood of thrombotic events at
3-year FU, while major bleeding was negligible across groups [22].
Of interest is the observation, that smoking had a signiﬁcant role in the
occurrence of bleeding in our study patients. In a recent study, smoking
was found to be a risk factor for serious bleeding [23]. Clopidogrel is
metabolically activated by several hepatic cytochrome P450 (CYP) iso-
enzymes, including CYP1A2; [24] cigarette smoking induces CYP1A2
[25] andmay, therefore, enhance the conversion of clopidogrel to its ac-
tive metabolite, associated with increased platelet inhibition and lower
aggregation as comparedwith nonsmokers [26]. These clinical observa-
tions may be explained by the adverse effects that smoking has on mu-
cosal aggressive and protective factors [27].7. Limitations
This is a single center non-randomized prospective study with the
decision about the duration of DAPLT after 12 months determined
by the physicians' discretion. Duration of DAPLT was widely variable,
and hidden compounders may be impossible to adjust; however there
were no differences on demographics and clinical or procedural charac-
teristics in patients on DAPLT vs. SAPLT treatment at any time period
after 12 months.
The study was conducted when only 1st generation DES were avail-
able, so the results could be considered as less relevant to current day
PCI-practice with newer DES designs. Furthermore, diabetic patients
often remain on DAPLT for a long period of time as a high risk subset
of patients or due to extensive cardiovascular disease.
Although clinical FU was completed in 96% of patients, there is still
a risk of under as well as over reporting of adverse events. Different
deﬁnitions of bleeding, other than TIMI or BARC deﬁnition used in this
study, could lead to different results about the safety of long-term anti-
platelet treatment.8. Conclusions
Prolong DAPLT increases the risk for bleeding (especially minor,
according to TIMI deﬁnition and type 1 or 2 according to BARC deﬁni-
tions) in DP, and this excess risk is steady for thewhole period of clinical
FU. Bleeding complications are not associated with increased risk of
deﬁnite/probable stent thrombosis orMACE. Acute coronary syndromes
and smokingmay have a signiﬁcant role in the occurrence of bleeding in
DP on DAPLT, but this observation needs further investigation.Conﬂict of interest
There is no conﬂict of interest to declare.
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